Teneligliptin belongs to the class of anti-diabetic drugs known as dipeptidyl peptidase-4 inhibitors or "gliptins” and is used for the treatment of type 2 diabetes mellitus.

Therapeutic Indication
Type 2 diabetes mellitus


Mechanism of Action:
Teneligliptin is a third generation DPP-4 inhibitor approved for treatment of type 2 diabetes. The mechanism of Teneligliptin is to increase incretin levels (GLP-1 and GIP), which inhibit glucagon release, which in turn increases insulin secretion, decreases gastric emptying, and decreases blood glucose levels.

Tmax was 1 hour and t1/2 was 18.9 hours. Maximum (89.7%) inhibition in plasma DPP-4 activity was noted within 2 hours and maintained >60% at 24 hours. Metabolism of teneligliptin was majorly mediated through CYP3A4, a cytochrome P450 isozyme.

Side Effects
Teneligliptin has been found to be well tolerated, and the safety profile is similar to other dipeptidyl peptidase 4 inhibitors. Hypoglycemia and constipation are the main adverse events.

● The risk or severity of hypoglycemia can be increased when Teneligliptin is combined with2,4-thiazolidinedione Acarbose Acetyl salicylic acid and Agmatine.
● Teneligliptin may increase the hypoglycemic activities of Acetohexamide.
● The therapeutic efficacy of Teneligliptin can be increased when used in combination with Acebutolol, Acetazolamide and Acetyl sulfisoxazole.

Some products that may interact with this drug include:
● Hypersensitivity to the drug or any of its components
● Severe ketosis
● Diabetic coma or pre-coma
● Immediate remedy in type 1 diabetes
● Severe trauma
● Before and after surgery
● When the blood glucose has to be controlled with insulin injection

Disclaimer:The data uploaded is made from content already available on internet.The company holds no right of it and is not responsible for any wrong information.